Results 201 to 210 of about 6,042 (221)

Plaatsbepaling guselkumab = Determining the role of guselkumab

Nederlands Tijdschrift voor Dermatologie en Venereologie, 2020
van Eijsden, Claire, van Doorn, Martijn
openaire   +1 more source

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Journal of the American Academy of Dermatology, 2017
Andrew Blauvelt, Ka Papp, Christopher Em Griffiths   +2 more
exaly  

Guselkumab for the treatment of psoriasis

Expert Opinion on Biological Therapy, 2018
Matteo Megna, Anna Balato, Annunziata Raimondo   +2 more
exaly  

Guselkumab zugelassen

Der Deutsche Dermatologe, 2018
openaire   +1 more source

Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study

Journal of Dermatology, 2018
Mamitaro Ohtsuki, Hiroshi Kubo, Hitomi Morishima   +2 more
exaly  

Apremilast/guselkumab/methotrexate

Reactions Weekly, 2023
openaire   +1 more source

Apremilast/guselkumab/secukinumab

Reactions Weekly, 2023
openaire   +1 more source

Guselkumab (Tremfya) for Psoriasis

JAMA, 2017
openaire   +2 more sources

Tremfya™ (Guselkumab).

Skinmed, 2019
William, Abramovits, Ali, Wiqas, Kimberly Dawn, Vincent, Sarah G, Versteeg, Aditya K, Gupta   +4 more
openaire   +1 more source

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

Lancet, The
exaly